---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-132565"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T03:43:48.181576+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Cabaletta to present CABA-201 preclinical data and DSG3-CAART update at ASGCT

## Summary
- Oral presentation on CD19 CAR T for SLE by CSO Samik Basu at ASGCT on May 16.
- New preclinical data for CABA-201 (CD19 CAR T) shows comparable activity to FMC63 construct.
- Updated DSG3-CAART clinical data shows enhanced persistence with IVIG/cyclophosphamide preconditioning.
- Poster presentations on May 18 and 19; abstracts published on ASGCT website.

## SEC filing metadata
- accession: 0001193125-23-132565
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312523132565/0001193125-23-132565-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312523132565/d134990d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-132565
- JSON: https://secwatch.observer/filing/0001193125-23-132565.json
- Plain text: https://secwatch.observer/filing/0001193125-23-132565.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.